{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-082184","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.139139+00:00","generated_at":"2026-06-09T02:55:56.330239+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio Q3 net loss $8.6M; XPro Phase II AD trial advances, INKmune on track","bullets":["Net loss $8.6M vs $7.7M YoY; R&D $6.0M; cash $41.8M as of Sept 30.","MHRA authorized XPro Phase II trial in early AD; recruitment increasing; top-line results expected end-2024.","FDA clinical hold on XPro for CNS expected to be lifted by end-2023.","INKmune Phase I/II in mCRPC to enroll first patient by year-end 2023; LAUREL trial in MDS/AML third site active."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-082184","json":"https://secwatch.observer/filing/0001213900-23-082184.json","markdown":"https://secwatch.observer/filing/0001213900-23-082184.md","text":"https://secwatch.observer/filing/0001213900-23-082184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023082184/0001213900-23-082184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023082184/ea187584-8k_inmunebio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:55:56.330239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea9654c2f648890e5bc32aee0068f06f29e48434","claim":"Inmune Bio, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 1, 2023, INmune Bio Inc. (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023082184/0001213900-23-082184-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}